NAGENiagen Bioscience, Inc.
Medicinal Chemicals & Botanical Products
- Revenue
- $129M
- 30% YoY
- Operating margin
- 12.6%
- 62% YoY
- EBITDA
- $17M
- 101% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- -3.5×
- −$60M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashFired78% of net incomeCash flow under 80% of net income
- Dilutive SBCClear5% of revenueOver 10% of revenue
- Payouts exceed cash flowClear2% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $67M | $72M | $84M | $100M | $129M | 30% |
| Operating income | −$27M | −$19M | −$6M | $8M | $16M | 111% |
| Net income | −$27M | −$17M | −$5M | $9M | $17M | 103% |
| Operating cash flow | −$24M | −$15M | $7M | $12M | $14M | 12% |
| Stock-based comp | $6M | $6M | $5M | $4M | $6M | 66% |
| Buybacks | — | — | — | $0 | $251K |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $8M | $10M | 133 | 148 |
| FY2024 | $1M | $3M | 111 | 117 |
| FY2023 | $1M | $1M | 30 | 113 |
| FY2022 | $1M | $843K | 35 | 113 |
| FY2021 | $1M | $2M | 78 | 111 |